These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 29778321)
21. Impact of Node Negative Target Volume Delineation on Contralateral Parotid Gland Dose Sparing Using IMRT in Head and Neck Cancer. Magnuson WJ; Urban E; Bayliss RA; Harari PM Technol Cancer Res Treat; 2015 Jun; 14(3):315-9. PubMed ID: 25782188 [TBL] [Abstract][Full Text] [Related]
22. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing. Rosenthal DI; Chambers MS; Weber RS; Eisbruch A Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519 [TBL] [Abstract][Full Text] [Related]
23. Parotid gland sparing with helical tomotherapy in head-and-neck cancer. Voordeckers M; Farrag A; Everaert H; Tournel K; Storme G; Verellen D; De Ridder M Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):443-8. PubMed ID: 22836056 [TBL] [Abstract][Full Text] [Related]
25. Functional outcomes of the modified submandibular gland transfer procedure. Murray S; Chung J; Zhang H; Baker S; Jha N; Scrimger R; Debenham B; Biron V; Harris J; O'Connell D; Seikaly H Laryngoscope; 2020 Apr; 130(4):925-929. PubMed ID: 31087663 [TBL] [Abstract][Full Text] [Related]
26. Risk factors and distribution features of level IB lymph nodes metastasis in nasopharyngeal carcinoma. Zeng L; Zhang Q; Ao F; Jiang CL; Xiao Y; Xie HH; Tang YQ; Gong XC; Li JG Auris Nasus Larynx; 2019 Jun; 46(3):457-464. PubMed ID: 30528104 [TBL] [Abstract][Full Text] [Related]
27. Sparing submandibular gland to alleviating acute xerostomia in patients with nasopharyngeal carcinoma treated with helical tomotherapy: Evaluation by diffusion kurtosis imaging. Zhao DW; Fan WJ; Fang XM; Luo YR; Wei J; Chen NX; Zhang XX; Liu G; Li JF; Zang X; Li M; Meng L; Ma L Radiother Oncol; 2022 Jul; 172():91-98. PubMed ID: 35584742 [TBL] [Abstract][Full Text] [Related]
28. The risk of level IB nodal involvement in oropharynx cancer: Guidance for submandibular gland sparing irradiation. Lee NCJ; Kelly JR; Park HS; Yarbrough WG; Burtness BA; Husain ZA Pract Radiat Oncol; 2017; 7(5):e317-e321. PubMed ID: 28356201 [TBL] [Abstract][Full Text] [Related]
29. Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing. Eisbruch A; Marsh LH; Dawson LA; Bradford CR; Teknos TN; Chepeha DB; Worden FP; Urba S; Lin A; Schipper MJ; Wolf GT Int J Radiat Oncol Biol Phys; 2004 May; 59(1):28-42. PubMed ID: 15093896 [TBL] [Abstract][Full Text] [Related]
30. Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control. Chajon E; Lafond C; Louvel G; Castelli J; Williaume D; Henry O; Jégoux F; Vauléon E; Manens JP; Le Prisé E; de Crevoisier R Radiat Oncol; 2013 May; 8():132. PubMed ID: 23721062 [TBL] [Abstract][Full Text] [Related]
31. A Model-Based Method for Assessment of Salivary Gland and Planning Target Volume Dosimetry in Volumetric-Modulated Arc Therapy Planning on Head-and-Neck Cancer. Zhang H; Cao Y; Antone J; Riegel AC; Ghaly M; Potters L; Jamshidi A J Med Phys; 2019; 44(3):201-206. PubMed ID: 31576068 [TBL] [Abstract][Full Text] [Related]
33. Methods for Reducing Normal Tissue Complication Probabilities in Oropharyngeal Cancer: Dose Reduction or Planning Target Volume Elimination. Samuels SE; Eisbruch A; Vineberg K; Lee J; Lee C; Matuszak MM; Ten Haken RK; Brock KK Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):645-52. PubMed ID: 27681761 [TBL] [Abstract][Full Text] [Related]
34. Comprehensive irradiation of head and neck cancer using conformal multisegmental fields: assessment of target coverage and noninvolved tissue sparing. Eisbruch A; Marsh LH; Martel MK; Ship JA; Ten Haken R; Pu AT; Fraass BA; Lichter AS Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):559-68. PubMed ID: 9635702 [TBL] [Abstract][Full Text] [Related]
35. 3D-conformal-intensity modulated radiotherapy with compensators for head and neck cancer: clinical results of normal tissue sparing. Wendt TG; Abbasi-Senger N; Salz H; Pinquart I; Koscielny S; Przetak SM; Wiezorek T Radiat Oncol; 2006 Jun; 1():18. PubMed ID: 16790059 [TBL] [Abstract][Full Text] [Related]
36. Sparing of normal tissues with volumetric arc radiation therapy for glioblastoma: single institution clinical experience. Briere TM; McAleer MF; Levy LB; Yang JN Radiat Oncol; 2017 May; 12(1):79. PubMed ID: 28464840 [TBL] [Abstract][Full Text] [Related]
37. Geometric factors influencing dosimetric sparing of the parotid glands using IMRT. Hunt MA; Jackson A; Narayana A; Lee N Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):296-304. PubMed ID: 16904529 [TBL] [Abstract][Full Text] [Related]
38. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer. Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418 [TBL] [Abstract][Full Text] [Related]
39. Three-dimensional dosimetric evaluation of a conventional radiotherapy technique for treatment of nasopharyngeal carcinoma. Chau RM; Teo PM; Choi PH; Cheung KY; Lee WY Radiother Oncol; 2001 Feb; 58(2):143-53. PubMed ID: 11166865 [TBL] [Abstract][Full Text] [Related]
40. Can dose reduction to one parotid gland prevent xerostomia?--A feasibility study for locally advanced head and neck cancer patients treated with intensity-modulated radiotherapy. Anand AK; Jain J; Negi PS; Chaudhoory AR; Sinha SN; Choudhury PS; Kumar R; Munjal RK Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):497-504. PubMed ID: 16909975 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]